Subtilosin
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Pericoital
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Rutgers, University of Alberta, Universidad de Buenos Aires
Details
- API: Subtilosin
-
Mechanism of Action:
- Inhibition of Sperm Capacitation
- Inhibition of Sperm Motility
- Anti-Microbial
- Regimen: On Demand
- MPT: Potential MPT
- Promising Attributes: Subtilosin may provide effective inhibition of sperm movement and activity, in addition to protection from infectious disease, without negatively impacting vaginal flora
Product Status
No Indication of Development after 2014. Spermicidal peptide development now focused on LL-37.
History
2008: Spermicidal effect of the peptide subtilosin confirmed in pre-clinical evaluation
2012: Controlled, blinded non-clinical study finds consistent inhibition of human sperm motility and viability by subtilosin
2014: Subtilosin's antiviral effect against HSV2 documented, furthering its potential use as an MPT